My group's research is based upon discovering the molecular basis of childhood cancer and translating this into improved patient outcomes. We are, through a combination of high-level interdisciplinary clusters that maintain the link between fundamental (scientists) and clinical (physicians) research, discovering unprecedented number of clinically relevant targets. We achieve efficient and effective translation of these targets through drug repositioning into potential new treatments for the patients. The integrated multidisciplinary solutions allow for seamless translation from discovery to clinical trial.